| A SARS-CoV-2 protein interaction map reveals targets for drug repurposing DE Gordon, GM Jang, M Bouhaddou, J Xu, K Obernier, KM White, ... Nature 583 (7816), 459-468, 2020 | 4769 | 2020 |
| The global phosphorylation landscape of SARS-CoV-2 infection M Bouhaddou*, D Memon*, B Meyer*, KM White*, VV Rezelj*, ... Cell 182 (3), 685-712. e19, 2020 | 963 | 2020 |
| SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution J Zahradník, S Marciano, M Shemesh, E Zoler, D Harari, J Chiaravalli, ... Nature microbiology 6 (9), 1188-1198, 2021 | 372 | 2021 |
| Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2 N Drayman, JK DeMarco, KA Jones, SA Azizi, HM Froggatt, K Tan, ... Science 373 (6557), 931-936, 2021 | 220 | 2021 |
| SARS-CoV-2 RBD in vitro evolution follows contagious mutation spread, yet generates an able infection inhibitor J Zahradnik, S Marciano, M Shemesh, E Zoler, J Chiaravalli, B Meyer, ... biorxiv, 2021 | 131 | 2021 |
| Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential B Meyer, J Chiaravalli, S Gellenoncourt, P Brownridge, DP Bryne, LA Daly, ... Nature Communications 12 (5553), 2021 | 110 | 2021 |
| Inhibition of innate immune responses is key to pathogenesis by arenaviruses B Meyer, H Ly Journal of virology 90 (8), 3810-3818, 2016 | 63 | 2016 |
| Defective viral genomes as therapeutic interfering particles against flavivirus infection in mammalian and mosquito hosts VV Rezelj, L Carrau, F Merwaiss, LI Levi, D Erazo, QD Tran, ... Nature Communications 12 (1), 2290, 2021 | 46 | 2021 |
| Staphylococcus aureus DinG, a helicase that has evolved into a nuclease AM McRobbie, B Meyer, C Rouillon, B Petrovic-Stojanovska, H Liu, ... Biochemical Journal 442 (1), 77-84, 2012 | 25 | 2012 |
| RNA-seq accuracy and reproducibility for the mapping and quantification of influenza defective viral genomes J Boussier, S Munier, E Achouri, B Meyer, B Crescenzo-Chaigne, ... RNA 26 (12), 1905-1918, 2020 | 19 | 2020 |
| Apoptosis during arenavirus infection: mechanisms and evasion strategies B Meyer, A Groseth Microbes and Infection 20 (2), 65-80, 2018 | 18 | 2018 |
| Characterisation of protease activity during SARS-CoV-2 infection identifies novel viral cleavage sites and cellular targets with therapeutic potential B Meyer, J Chiaravalli, S Gellenoncourt, P Brownridge, DP Bryne, LA Daly, ... BioRxiv, 2020.09. 16.297945, 2020 | 16 | 2020 |
| The New World Arenavirus Tacaribe induces caspase-dependent apoptosis in infected cells S Wolff, A Groseth, B Meyer, D Jackson, T Strecker, A Kaufmann, ... Journal of General Virology, 2016 | 16 | 2016 |
| A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing [internet] DE Gordon, GM Jang, M Bouhaddou, J Xu, K Obernier, MJ O’Meara Syst Biol, 2020 | 3 | 2020 |
| Immunosuppression by hemorrhagic fever-causing viruses B Meyer, H Ly Oncotarget 6 (42), 44057-44058, 2015 | 1 | 2015 |
| Lautropia mirabilis sepsis in immunodeficiency: first report and genomic features S Genseke, M Berisha, A Teerstegen, B Meyer, AJ Kaasch, J Färber, ... Infection, 1-6, 2024 | | 2024 |
| Defective interfering viral genomes M Vignuzzi, B Meyer, V Rezelj, L Levi, V Bernhauerova, T Vallet, T Pieplu, ... US Patent App. 17/907,424, 2023 | | 2023 |
| 6-6 or 5-6 fused bicyclic compounds comprising a pyri(mi)dine ring useful in the treatment of infectious diseases J Chiaravalli, J Guillon, M Lavigne, H Munier-Lehmann, JL Mergny, ... WO Patent WO2022129376A1, 2022 | | 2022 |
| Activated reporter protein for the detection of infection in a biological sample B Meyer, M Vignuzzi WO Patent WO2022003184A1, 2022 | | 2022 |
| Defective interfering viral genomes M Vignuzzi, B Meyer, V Rezelj, L Levi, V Bernhauerova, T Vallet, T Pieplu, ... WO Patent WO2021191688A1, 2021 | | 2021 |